Skip Navigation LinksHome   >   Research & Development   >   Pipeline


OCT combines the potential of natural plant molecules with the scientific rigour of pharmaceutical R&D practices to establish itself as a growing leader in cannabinoid pharmaceutical drug development. OCT is tackling the problem of the pain pandemic, focusing on indications with untreatable severe pain as well as orphan indications.

The OCT cannabinoid discovery engine uses a balanced drug product strategy that employs both natural and synthetic compounds to develop safe, effective, and non-addictive prescription medicines that have undergone randomised clinical trials (RCT) to achieve regulatory marketing approval and pharmaceutical GMP manufactured medicines that are prescribed in a quality and dose-consistent manner.

By using four different inputs we are building a portfolio of drug candidates that is balanced for time to market, market size and cost to develop.

Our lead drug candidate OCT461201, the precursor of our in-licensing approach, is entering the late stages of the pre-clinical development for post-herpetic neuralgia (PHN) and irritable bowel syndrome (IBS) and it will enter clinical trials in 2022.

Combinations of unmodified phytocannabinoids (pCBs) provide our second input which can be developed to target trigeminal neuralgia (TN). Orphan drug designation will allow us to retain market exclusivity through regulatory protections, enabling an accelerated route to first-time-in-human (FTiH).

OCT’s proprietary library delivers a third line of potential drugs that have longer developmental timelines but are unique to the company and can be applied to a broad range of high-value indications, with particular focus on severe neuralgia conditions.

OCT aims for a global footprint by commissioning new research and by developing a novel-target approach to deliver a potential first-in-class drug and our fourth candidate for the treatment of neuralgias.